# EDGAR Filing Document

**Accession Number:** 0000826644
**File Stem:** 0001752724-23-075910
**Filing Date:** 2023-3
**Character Count:** 52888
**Document Hash:** 309547c4b7edca8ffed0ae0b5c7f423e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001752724-23-075910.hdr.sgml**: 20230331

**ACCESSION NUMBER**: 0001752724-23-075910

**CONFORMED SUBMISSION TYPE**: NPORT-P

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230131

**FILED AS OF DATE**: 20230331

**DATE AS OF CHANGE**: 20230331

**PERIOD START**: 20231031

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AIM INVESTMENT FUNDS (INVESCO INVESTMENT FUNDS)
- **CENTRAL INDEX KEY:** 0000826644
- **IRS NUMBER:** 000000000
- **FISCAL YEAR END:** 1031

**FILING VALUES:**
- **FORM TYPE:** NPORT-P
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-05426
- **FILM NUMBER:** 23786069

**BUSINESS ADDRESS:**
- **STREET 1:** 11 GREENWAY PLAZA
- **STREET 2:** SUITE 1000
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77046
- **BUSINESS PHONE:** 7136261919

**MAIL ADDRESS:**
- **STREET 1:** 11 GREENWAY PLAZA
- **STREET 2:** SUITE 1000
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77046

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AIM INVESTMENT FUNDS
- **DATE OF NAME CHANGE:** 19980529

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** G T INVESTMENT FUNDS INC
- **DATE OF NAME CHANGE:** 19920703

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** G T GLOBAL INCOME SERIES INC
- **DATE OF NAME CHANGE:** 19890521

## Series and Classes Contracts Data

### INVESCO Health Care Fund (Series ID: S000000235)

| Class ID   | Class Name     | Ticker Symbol   |
|:---|:---|:---|
| C000000565 | Class A        | GGHCX           |
| C000000567 | Class C        | GTHCX           |
| C000029647 | Investor Class | GTHIX           |
| C000071224 | Class Y        | GGHYX           |
| C000188882 | Class R6       |  |

## Nport-Ex

### Schedule of Investments<sup>(a)</sup>
*January 31, 2023*

(Unaudited)

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**Shares** | &nbsp;&nbsp;**Shares** | &nbsp;&nbsp;**Value** |
| **Common Stocks & Other Equity Interests–97.10%** | **Common Stocks & Other Equity Interests–97.10%** | **Common Stocks & Other Equity Interests–97.10%** |
| **Biotechnology–22.14%** | **Biotechnology–22.14%** | **Biotechnology–22.14%** |
| AbbVie, Inc. | 374821 | &nbsp;&nbsp;&nbsp;&nbsp; $55379803 |
| Alnylam Pharmaceuticals, Inc.<sup>(b)</sup> | &nbsp;&nbsp;59846 | &nbsp;&nbsp; 13549134 |
| Amgen, Inc. | &nbsp;&nbsp;89600 | &nbsp;&nbsp; 22615040 |
| Argenx SE, ADR (Netherlands)<sup>(b)</sup> | &nbsp;&nbsp;37892 | &nbsp;&nbsp; 14484217 |
| Ascendis Pharma A/S, ADR (Denmark)<sup>(b)</sup> | &nbsp;&nbsp;23555 | &nbsp;&nbsp; 2922704 |
| BioCryst Pharmaceuticals, Inc.<sup>(b)(c)</sup> | 131925 | &nbsp;&nbsp; 1391809 |
| Biogen, Inc.<sup>(b)</sup> | &nbsp;&nbsp;42202 | &nbsp;&nbsp; 12276562 |
| BioMarin Pharmaceutical, Inc.<sup>(b)</sup> | &nbsp;&nbsp;65250 | &nbsp;&nbsp; 7526587 |
| CSL Ltd. (Australia) | &nbsp;&nbsp;21756 | &nbsp;&nbsp; 4592173 |
| Cytokinetics, Inc.<sup>(b)(c)</sup> | &nbsp;&nbsp;51827 | &nbsp;&nbsp; 2201611 |
| Genmab A/S, ADR (Denmark)<sup>(b)(c)</sup> | 195994 | &nbsp;&nbsp; 7673165 |
| Gilead Sciences, Inc. | 114354 | &nbsp;&nbsp; 9598875 |
| Halozyme Therapeutics, Inc.<sup>(b)(c)</sup> | 188563 | &nbsp;&nbsp; 9761907 |
| Incyte Corp.<sup>(b)</sup> | 170369 | &nbsp;&nbsp; 14505217 |
| IVERIC bio, Inc.<sup>(b)</sup> | 147129 | &nbsp;&nbsp; 3398680 |
| Karuna Therapeutics, Inc.<sup>(b)(c)</sup> | &nbsp;&nbsp;14296 | &nbsp;&nbsp; 2850479 |
| Legend Biotech Corp., ADR<sup>(b)(c)</sup> | &nbsp;&nbsp;55054 | &nbsp;&nbsp; 2780227 |
| Moderna, Inc.<sup>(b)</sup> | &nbsp;&nbsp;32630 | &nbsp;&nbsp; 5744838 |
| Neurocrine Biosciences, Inc.<sup>(b)</sup> | 100963 | &nbsp;&nbsp; 11199826 |
| Regeneron Pharmaceuticals, Inc.<sup>(b)</sup> | &nbsp;&nbsp;41988 | &nbsp;&nbsp; 31846638 |
| Sarepta Therapeutics, Inc.<sup>(b)</sup> | &nbsp;&nbsp;47185 | &nbsp;&nbsp; 5896709 |
| United Therapeutics Corp.<sup>(b)</sup> | &nbsp;&nbsp;34400 | &nbsp;&nbsp; 9053048 |
| Vertex Pharmaceuticals, Inc.<sup>(b)</sup> | 132504 | &nbsp;&nbsp; 42812042 |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;294061291 |
| **Health Care Distributors–4.67%** | **Health Care Distributors–4.67%** | **Health Care Distributors–4.67%** |
| AdaptHealth Corp.<sup>(b)</sup> | 108746 | &nbsp;&nbsp; 2330427 |
| AmerisourceBergen Corp. | 177579 | &nbsp;&nbsp; 30003748 |
| McKesson Corp. | &nbsp;&nbsp;78471 | &nbsp;&nbsp; 29715398 |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;62049573 |
| **Health Care Equipment–16.10%** | **Health Care Equipment–16.10%** | **Health Care Equipment–16.10%** |
| AtriCure, Inc.<sup>(b)</sup> | &nbsp;&nbsp;95647 | &nbsp;&nbsp; 4139602 |
| Axonics, Inc.<sup>(b)(c)</sup> | &nbsp;&nbsp;98138 | &nbsp;&nbsp; 6025673 |
| Becton, Dickinson and Co. | &nbsp;&nbsp;38540 | &nbsp;&nbsp; 9720559 |
| Boston Scientific Corp.<sup>(b)</sup> | 726014 | &nbsp;&nbsp; 33578147 |
| DexCom, Inc.<sup>(b)</sup> | 190788 | &nbsp;&nbsp; 20431487 |
| Globus Medical, Inc., Class A<sup>(b)(c)</sup> | 114436 | &nbsp;&nbsp; 8639918 |
| IDEXX Laboratories, Inc.<sup>(b)</sup> | &nbsp;&nbsp;23438 | &nbsp;&nbsp; 11261959 |
| Inari Medical, Inc.<sup>(b)(c)</sup> | &nbsp;&nbsp;44092 | &nbsp;&nbsp; 2515449 |
| Inspire Medical Systems, Inc.<sup>(b)</sup> | &nbsp;&nbsp;46682 | &nbsp;&nbsp; 11813347 |
| Insulet Corp.<sup>(b)</sup> | &nbsp;&nbsp;51713 | &nbsp;&nbsp; 14858179 |
| Intuitive Surgical, Inc.<sup>(b)</sup> | 113636 | &nbsp;&nbsp; 27919229 |
| iRhythm Technologies, Inc.<sup>(b)</sup> | &nbsp;&nbsp;41132 | &nbsp;&nbsp; 4043276 |
| Penumbra, Inc.<sup>(b)</sup> | &nbsp;&nbsp;&nbsp;&nbsp;7257 | &nbsp;&nbsp; 1817225 |
| ResMed, Inc. | &nbsp;&nbsp;47932 | &nbsp;&nbsp; 10946231 |
| Shockwave Medical, Inc.<sup>(b)</sup> | &nbsp;&nbsp;49050 | &nbsp;&nbsp; 9217966 |
| Stryker Corp. | 145379 | &nbsp;&nbsp; 36898644 |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;213826891 |
| **Health Care Facilities–2.54%** | **Health Care Facilities–2.54%** | **Health Care Facilities–2.54%** |
| Acadia Healthcare Co., Inc.<sup>(b)</sup> | 110906 | &nbsp;&nbsp; 9318322 |
| Encompass Health Corp. | &nbsp;&nbsp;79801 | &nbsp;&nbsp; 4983572 |
| HCA Healthcare, Inc. | &nbsp;&nbsp;51071 | &nbsp;&nbsp; 13026680 |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**Shares** | &nbsp;&nbsp;**Shares** | &nbsp;&nbsp;**Value** |
| **Health Care Facilities–(continued)** | **Health Care Facilities–(continued)** | **Health Care Facilities–(continued)** |
| Surgery Partners, Inc.<sup>(b)</sup> | 193939 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; $6438775 |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;33767349 |
| **Health Care Services–1.18%** | **Health Care Services–1.18%** | **Health Care Services–1.18%** |
| AMN Healthcare Services, Inc.<sup>(b)</sup> | &nbsp;&nbsp;47918 | &nbsp;&nbsp; 4592461 |
| Guardant Health, Inc.<sup>(b)(c)</sup> | &nbsp;&nbsp;54363 | &nbsp;&nbsp; 1708629 |
| Option Care Health, Inc.<sup>(b)</sup> | 219830 | &nbsp;&nbsp; 6346492 |
| Privia Health Group, Inc.<sup>(b)(c)</sup> | 113291 | &nbsp;&nbsp; 3063389 |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15710971 |
| **Health Care Supplies–0.89%** | **Health Care Supplies–0.89%** | **Health Care Supplies–0.89%** |
| Cooper Cos., Inc. (The) | &nbsp;&nbsp;14506 | &nbsp;&nbsp; 5061579 |
| Lantheus Holdings, Inc.<sup>(b)</sup> | &nbsp;&nbsp;29929 | &nbsp;&nbsp; 1720917 |
| Silk Road Medical, Inc.<sup>(b)</sup> | &nbsp;&nbsp;92695 | &nbsp;&nbsp; 5038900 |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11821396 |
| **Health Care Technology–0.36%** | **Health Care Technology–0.36%** | **Health Care Technology–0.36%** |
| Evolent Health, Inc., Class A<sup>(b)</sup> | 147949 | &nbsp;&nbsp; 4766917 |
| **Life Sciences Tools & Services–13.04%** | **Life Sciences Tools & Services–13.04%** | **Life Sciences Tools & Services–13.04%** |
| 10X Genomics, Inc., Class A<sup>(b)</sup> | &nbsp;&nbsp;36268 | &nbsp;&nbsp; 1698430 |
| Agilent Technologies, Inc. | 184139 | &nbsp;&nbsp; 28003859 |
| Bio-Techne Corp. | &nbsp;&nbsp;37537 | &nbsp;&nbsp; 2990197 |
| Danaher Corp. | 167320 | &nbsp;&nbsp; 44236062 |
| IQVIA Holdings, Inc.<sup>(b)</sup> | &nbsp;&nbsp;48273 | &nbsp;&nbsp; 11074309 |
| Lonza Group AG (Switzerland) | &nbsp;&nbsp;&nbsp;&nbsp;4584 | &nbsp;&nbsp; 2616891 |
| Maravai LifeSciences Holdings, Inc., Class A<sup>(b)</sup> | 147526 | &nbsp;&nbsp; 2162731 |
| Medpace Holdings, Inc.<sup>(b)</sup> | &nbsp;&nbsp;24944 | &nbsp;&nbsp; 5514370 |
| Mettler-Toledo International, Inc.<sup>(b)</sup> | &nbsp;&nbsp;&nbsp;&nbsp;7117 | &nbsp;&nbsp; 10909792 |
| Repligen Corp.<sup>(b)(c)</sup> | &nbsp;&nbsp;62232 | &nbsp;&nbsp; 11531590 |
| Thermo Fisher Scientific, Inc. | &nbsp;&nbsp;91896 | &nbsp;&nbsp; 52411046 |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;173149277 |
| **Managed Health Care–15.00%** | **Managed Health Care–15.00%** | **Managed Health Care–15.00%** |
| Elevance Health, Inc. | &nbsp;&nbsp;33495 | &nbsp;&nbsp; 16747165 |
| Humana, Inc. | &nbsp;&nbsp;90008 | &nbsp;&nbsp; 46057094 |
| Molina Healthcare, Inc.<sup>(b)</sup> | &nbsp;&nbsp;56068 | &nbsp;&nbsp; 17483684 |
| UnitedHealth Group, Inc. | 238401 | &nbsp;&nbsp; 119007395 |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;199295338 |
| **Pharmaceuticals–21.18%** | **Pharmaceuticals–21.18%** | **Pharmaceuticals–21.18%** |
| AstraZeneca PLC (United Kingdom) | &nbsp;&nbsp;40217 | &nbsp;&nbsp; 5261924 |
| AstraZeneca PLC, ADR (United Kingdom) | 557703 | &nbsp;&nbsp; 36457045 |
| Axsome Therapeutics, Inc.<sup>(b)(c)</sup> | &nbsp;&nbsp;29000 | &nbsp;&nbsp; 2175000 |
| Eli Lilly and Co. | 255385 | &nbsp;&nbsp; 87890748 |
| Harmony Biosciences Holdings, Inc.<sup>(b)</sup> | &nbsp;&nbsp;70914 | &nbsp;&nbsp; 3415927 |
| Intra-Cellular Therapies, Inc.<sup>(b)</sup> | &nbsp;&nbsp;83473 | &nbsp;&nbsp; 4000026 |
| Merck & Co., Inc. | 622892 | &nbsp;&nbsp; 66904830 |
| Novo Nordisk A/S, Class B (Denmark) | 348520 | &nbsp;&nbsp; 48264310 |
| Roche Holding AG | &nbsp;&nbsp;16483 | &nbsp;&nbsp; 5151487 |
| Royalty Pharma PLC, Class A | 266252 | &nbsp;&nbsp; 10434416 |
| Zoetis, Inc. | &nbsp;&nbsp;68314 | &nbsp;&nbsp; 11305284 |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;281260997 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Common Stocks & Other Equity Interests (Cost $922,233,848) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Common Stocks & Other Equity Interests (Cost $922,233,848) | &nbsp;&nbsp;&nbsp;&nbsp;1289710000 |

---

See accompanying notes which are an integral part of this schedule.

Invesco Health Care Fund

------

---

| | | | |
|:---|:---|:---|:---|
|  | &nbsp;&nbsp;**Shares** | &nbsp;&nbsp;**Shares** | &nbsp;&nbsp;**Value** |
| **Money Market Funds–2.97%** | **Money Market Funds–2.97%** | **Money Market Funds–2.97%** | **Money Market Funds–2.97%** |
| Invesco Government & Agency Portfolio, Institutional Class, 4.30%<sup>(d)(e)</sup> | Invesco Government & Agency Portfolio, Institutional Class, 4.30%<sup>(d)(e)</sup> | 13585536 | &nbsp;&nbsp;&nbsp;&nbsp; $13585537 |
| Invesco Liquid Assets Portfolio, Institutional Class, 4.48%<sup>(d)(e)</sup> | Invesco Liquid Assets Portfolio, Institutional Class, 4.48%<sup>(d)(e)</sup> | 10352287 | &nbsp;&nbsp; 10355392 |
| Invesco Treasury Portfolio, Institutional Class, 4.30%<sup>(d)(e)</sup> | Invesco Treasury Portfolio, Institutional Class, 4.30%<sup>(d)(e)</sup> | 15526327 | &nbsp;&nbsp; 15526327 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Money Market Funds (Cost $39,463,251) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Money Market Funds (Cost $39,463,251) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Money Market Funds (Cost $39,463,251) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;39467256 |
| TOTAL INVESTMENTS IN SECURITIES (excluding investments purchased with cash collateral from securities on loan)-100.07% (Cost $961,697,099) |  |  | &nbsp;&nbsp;&nbsp;&nbsp;1329177256 |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**Shares** | &nbsp;&nbsp;**Shares** | &nbsp;&nbsp;**Value** |
| **Investments Purchased with Cash Collateral from Securities on Loan** | **Investments Purchased with Cash Collateral from Securities on Loan** | **Investments Purchased with Cash Collateral from Securities on Loan** |
| **Money Market Funds–2.55%** | **Money Market Funds–2.55%** | **Money Market Funds–2.55%** |
| Invesco Private Government Fund, 4.36%<sup>(d)(e)(f)</sup> | &nbsp;&nbsp;9466816 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; $9466816 |
| Invesco Private Prime Fund, 4.59%<sup>(d)(e)(f)</sup> | 24338474 | &nbsp;&nbsp; 24345775 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Investments Purchased with Cash Collateral from Securities on Loan (Cost $33,812,116) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Investments Purchased with Cash Collateral from Securities on Loan (Cost $33,812,116) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;33812591 |
| TOTAL INVESTMENTS IN SECURITIES–102.62% (Cost $995,509,215) | TOTAL INVESTMENTS IN SECURITIES–102.62% (Cost $995,509,215) | &nbsp;&nbsp;&nbsp;&nbsp;1362989847 |
| OTHER ASSETS LESS LIABILITIES—(2.62)% | OTHER ASSETS LESS LIABILITIES—(2.62)% | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(34815212) |
| NET ASSETS–100.00% | NET ASSETS–100.00% | &nbsp;&nbsp;$1328174635 |

---

Investment Abbreviations:

ADR – American Depositary Receipt

Notes to Schedule of Investments:

<sup>(a)</sup> Industry and/or sector classifications used in this report are generally according to the Global Industry Classification Standard, which was developed by and is the exclusive property and a service mark of MSCI Inc. and Standard & Poor's.

<sup>(b)</sup> Non-income producing security.

<sup>(c)</sup> All or a portion of this security was out on loan at January 31, 2023.

<sup>(d)</sup> Affiliated issuer. The issuer and/or the Fund is a wholly-owned subsidiary of Invesco Ltd., or is affiliated by having an investment adviser that is under common control of Invesco Ltd. The table below shows the Fund's transactions in, and earnings from, its investments in affiliates for the three months ended January 31, 2023.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Value<br> October 31, 2022** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Purchases<br> at Cost** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Proceeds<br> from Sales** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Change in<br> Unrealized<br> Appreciation<br> (Depreciation)** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Realized<br> Gain** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Value<br> January 31, 2023** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Dividend Income** |
| **Investments in Affiliated Money Market Funds:** |  |  |  |  |  |  |  |
| Invesco Government & Agency Portfolio, Institutional Class | $16763030 | &nbsp;&nbsp;&nbsp;&nbsp;$24002796 | &nbsp;&nbsp;&nbsp;&nbsp;$(27180289) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$- | &nbsp;&nbsp;&nbsp;&nbsp;$13585537 | &nbsp;&nbsp;&nbsp;&nbsp;$107763 |
| Invesco Liquid Assets Portfolio, Institutional Class | &nbsp;&nbsp;&nbsp;12624352 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17144855 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(19414493) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1161) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1839 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10355392 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;86878 |
| Invesco Treasury Portfolio, Institutional Class | &nbsp;&nbsp;&nbsp;19157749 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27431766 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(31063188) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15526327 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;123442 |
| **Investments Purchased with Cash Collateral from Securities on Loan:** |  |  |  |  |  |  |  |
| Invesco Private Government Fund | &nbsp;&nbsp;&nbsp;10015507 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23886899 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(24435590) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9466816 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;80,292\* |
| Invesco Private Prime Fund | &nbsp;&nbsp;&nbsp;27798816 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;60258407 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(63718642) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;465 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6729 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;24345775 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;220,086\* |
| Total | $86359454 | &nbsp;&nbsp;&nbsp;&nbsp;$152724723 | &nbsp;&nbsp;&nbsp;&nbsp;$(165812202) | &nbsp;&nbsp;&nbsp;&nbsp;$(696) | &nbsp;&nbsp;&nbsp;&nbsp;$8568 | &nbsp;&nbsp;&nbsp;&nbsp;$73279847 | &nbsp;&nbsp;&nbsp;&nbsp;$618461 |

---

\* Represents the income earned on the investment of cash collateral. Does not include rebates and fees paid to lending agent or premiums received from borrowers, if any.

<sup>(e)</sup> The rate shown is the 7-day SEC standardized yield as of January 31, 2023. <br> <sup>(f)</sup> The security has been segregated to satisfy the commitment to return the cash collateral received in securities lending transactions upon the borrower's return of the securities loaned.

The valuation policy and a listing of other significant accounting policies are available in the most recent shareholder report.

See accompanying notes which are an integral part of this schedule.

Invesco Health Care Fund

------

### Notes to Quarterly Schedule of Portfolio Holdings
*January 31, 2023*

(Unaudited)

#### NOTE 1—Additional Valuation Information
Generally Accepted Accounting Principles ("GAAP") defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, under current market conditions. GAAP establishes a hierarchy that prioritizes the inputs to valuation methods, giving the highest priority to readily available unadjusted quoted prices in an active market for identical assets (Level 1) and the lowest priority to significant unobservable inputs (Level 3), generally when market prices are not readily available. Based on the valuation inputs, the securities or other investments are tiered into one of three levels. Changes in valuation methods may result in transfers in or out of an investment's assigned level:

Level 1 – Prices are determined using quoted prices in an active market for identical assets.

Level 2 – Prices are determined using other significant observable inputs. Observable inputs are inputs that other market participants may use in pricing a security. These may include quoted prices for similar securities, interest rates, prepayment speeds, credit risk, yield curves, loss severities, default rates, discount rates, volatilities and others.

Level 3 – Prices are determined using significant unobservable inputs. In situations where quoted prices or observable inputs are unavailable (for example, when there is little or no market activity for an investment at the end of the period), unobservable inputs may be used. Unobservable inputs reflect Invesco Advisers, Inc.'s assumptions about the factors market participants would use in determining fair value of the securities or instruments and would be based on the best available information.

The following is a summary of the tiered valuation input levels, as of January 31, 2023. The level assigned to the securities valuations may not be an indication of the risk or liquidity associated with investing in those securities. Because of the inherent uncertainties of valuation, the values reflected in the financial statements may materially differ from the value received upon actual sale of those investments.

---

| | | | | |
|:---|:---|:---|:---|:---|
| <br>**Investments in Securities** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Level 1**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Level 2**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Level 3**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total**  |
| Common Stocks & Other Equity Interests | &nbsp;&nbsp;&nbsp;&nbsp;$1223823215 | &nbsp;&nbsp;&nbsp;&nbsp;$65886785 | &nbsp;&nbsp;&nbsp;&nbsp;$— | &nbsp;&nbsp;&nbsp;&nbsp;$1289710000 |
| Money Market Funds | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;39467256 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;33812591 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;— | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;73279847 |
| &nbsp;&nbsp;&nbsp;**Total Investments** | &nbsp;&nbsp;&nbsp;&nbsp;$1263290471 | &nbsp;&nbsp;&nbsp;&nbsp;$99699376 | &nbsp;&nbsp;&nbsp;&nbsp;$— | &nbsp;&nbsp;&nbsp;&nbsp;$1362989847 |

---

Invesco Health Care Fund

## Form NPORT-P: Monthly Portfolio Investments Report

### NPORT-P: Part A: General Information

**Item A.1. Information about the Registrant.**

- **a. Name of Registrant:** AIM Investment Funds (Invesco Investment Funds)

- **b. Investment Company Act file number:** 811-05426

- **c. CIK number of Registrant:** 0000826644

- **d. LEI of Registrant:** Y5W0BJB7U2X9V6NIC803

- **e. Address and telephone number of Registrant.**

  - **Street Address 1:** 11 Greenway Plaza

  - **City:** Houston

  - **State:** TX

  - **Foreign country:** US

  - **Zip / Postal Code:** 77046-1173

  - **Telephone number:** 800-959-4246

**Item A.2. Information about the Series.**

- **a. Name of Series:** Invesco Health Care Fund

- **b. EDGAR series identifier (if any):** S000000235

- **c. LEI of Series:** 549300BBEGFRGDDJRQ35

**Item A.3. Reporting period.**

- **a. Date of fiscal year-end:** 2023-10-31

- **b. Date as of which information is reported:** 2023-01-31

**Item A.4. Final filing**

Does the Fund anticipate that this will be its final filing on Form N-PORT? **No**

### Fund Information

**Total Assets:** $1363544980.49

**Total Liabilities:** $34813855.99

**Net Assets:** $1328731124.50

**Cash Not Reported:** $1008.73

**Monthly Return Information**

| Class               | Month 1 Return (%)   | Month 2 Return (%)   | Month 3 Return (%)   |
|:---|:---|:---|:---|
| Class ID C000029647 | 4.31%                | -2.33%               | -1.50%               |
| Class ID C000071224 | 4.32%                | -2.30%               | -1.47%               |
| Class ID C000000567 | 4.21%                | -2.35%               | -1.56%               |
| Class ID C000000565 | 4.31%                | -2.33%               | -1.47%               |
| Class ID C000188882 | 4.30%                | -2.29%               | -1.46%               |

**Monthly Gains & Losses**

| Period   | Net Realized Gain/Loss   | Net Unrealized Appreciation/Depreciation   |
|:---|:---|:---|
| Month 1  | $-8641925.76             | $66436332.06                               |
| Month 2  | $1352264.77              | $-34175574.04                              |
| Month 3  | $2222138.14              | $-21942662.19                              |

### Schedule of Portfolio Investments

| Name                                  | Title                                                      | Identifiers                                   | Payoff Profile   | Asset Category   | Issuer Category   | Country   |   Balance | Units   | Value (USD)   | % of Net Assets   | Maturity Date   | Coupon Type   | Annualized Rate (%)   | Restricted?   |   Fair Value Level | Lending Status   |
|:---|:---|:---|:---|:---|:---|:---|---:|:---|:---|:---|:---|:---|:---|:---|---:|:---|
| Invesco Treasury Portfolio            | Invesco Treasury Portfolio, Institutional Class            | CUSIP: 825252406<br>LEI: 5493004B3TM8ZIDDDC39 | Long             | STIV             | RF                | US        |  15526327 | NS      | $15526327.19  | 1.17%             |  |  |  | No            |                  1 | On Loan: No      |
| CSL Ltd.                              | CSL Ltd.                                                   | CUSIP: N/A<br>LEI: 529900ECSECK5ZDQTE14       | Long             | EC               | CORP              | AU        |     21756 | NS      | $4592172.58   | 0.35%             |  |  |  | No            |                  2 | On Loan: No      |
| United Therapeutics Corp.             | United Therapeutics Corp.                                  | CUSIP: 91307C102<br>LEI: 5299005C4HZL4UWROC14 | Long             | EC               | CORP              | US        |     34400 | NS      | $9053048.00   | 0.68%             |  |  |  | No            |                  1 | On Loan: No      |
| Axonics, Inc.                         | Axonics, Inc.                                              | CUSIP: 05465P101<br>LEI: 549300LJY4X7N57VJL05 | Long             | EC               | CORP              | US        |     98138 | NS      | $6025673.20   | 0.45%             |  |  |  | No            |                  1 | On Loan: —       |
| BioMarin Pharmaceutical Inc.          | BioMarin Pharmaceutical Inc.                               | CUSIP: 09061G101<br>LEI: NSLL8ITTRR0J5HEMR848 | Long             | EC               | CORP              | US        |     65250 | NS      | $7526587.50   | 0.57%             |  |  |  | No            |                  1 | On Loan: No      |
| Option Care Health, Inc.              | Option Care Health, Inc.                                   | CUSIP: 68404L201<br>LEI: 549300DI3Q5ACSYJRI17 | Long             | EC               | CORP              | US        |    219830 | NS      | $6346492.10   | 0.48%             |  |  |  | No            |                  1 | On Loan: No      |
| Eli Lilly and Co.                     | Eli Lilly and Co.                                          | CUSIP: 532457108<br>LEI: FRDRIPF3EKNDJ2CQJL29 | Long             | EC               | CORP              | US        |    255385 | NS      | $87890747.75  | 6.61%             |  |  |  | No            |                  1 | On Loan: No      |
| Danaher Corp.                         | Danaher Corp.                                              | CUSIP: 235851102<br>LEI: S4BKK9OTCEWQ3YHPFM11 | Long             | EC               | CORP              | US        |    167320 | NS      | $44236061.60  | 3.33%             |  |  |  | No            |                  1 | On Loan: No      |
| Stryker Corp.                         | Stryker Corp.                                              | CUSIP: 863667101<br>LEI: 5493002F0SC4JTBU5137 | Long             | EC               | CORP              | US        |    145379 | NS      | $36898643.99  | 2.78%             |  |  |  | No            |                  1 | On Loan: No      |
| Medpace Holdings, Inc.                | Medpace Holdings, Inc.                                     | CUSIP: 58506Q109<br>LEI: 549300H8TYEUVTW14A54 | Long             | EC               | CORP              | US        |     24944 | NS      | $5514370.08   | 0.42%             |  |  |  | No            |                  1 | On Loan: No      |
| Repligen Corp.                        | Repligen Corp.                                             | CUSIP: 759916109<br>LEI: 54930006QJ0T5AUO1E71 | Long             | EC               | CORP              | US        |     62232 | NS      | $11531589.60  | 0.87%             |  |  |  | No            |                  1 | On Loan: —       |
| Neurocrine Biosciences, Inc.          | Neurocrine Biosciences, Inc.                               | CUSIP: 64125C109<br>LEI: 549300FECER0XBN49756 | Long             | EC               | CORP              | US        |    100963 | NS      | $11199825.59  | 0.84%             |  |  |  | No            |                  1 | On Loan: No      |
| Boston Scientific Corp.               | Boston Scientific Corp.                                    | CUSIP: 101137107<br>LEI: Y6ZDD9FP4P8JSSJMW954 | Long             | EC               | CORP              | US        |    726014 | NS      | $33578147.50  | 2.53%             |  |  |  | No            |                  1 | On Loan: No      |
| Biogen Inc.                           | Biogen Inc.                                                | CUSIP: 09062X103<br>LEI: W8J5WZB5IY3K0NDQT671 | Long             | EC               | CORP              | US        |     42202 | NS      | $12276561.80  | 0.92%             |  |  |  | No            |                  1 | On Loan: No      |
| Mettler-Toledo International Inc.     | Mettler-Toledo International Inc.                          | CUSIP: 592688105<br>LEI: 5493000BD5GJNUDIUG10 | Long             | EC               | CORP              | US        |      7117 | NS      | $10909791.64  | 0.82%             |  |  |  | No            |                  1 | On Loan: No      |
| ResMed Inc.                           | ResMed Inc.                                                | CUSIP: 761152107<br>LEI: 529900T3QE5253CCXF22 | Long             | EC               | CORP              | US        |     47932 | NS      | $10946230.84  | 0.82%             |  |  |  | No            |                  1 | On Loan: No      |
| Royalty Pharma PLC                    | Royalty Pharma PLC, Class A                                | CUSIP: G7709Q104<br>LEI: 549300FGFN7VOK8BZR03 | Long             | EC               | CORP              | GB        |    266252 | NS      | $10434415.88  | 0.79%             |  |  |  | No            |                  1 | On Loan: No      |
| Novo Nordisk A/S                      | Novo Nordisk A/S, Class B                                  | CUSIP: N/A<br>LEI: 549300DAQ1CVT6CXN342       | Long             | EC               | CORP              | DK        |    348520 | NS      | $48264309.89  | 3.63%             |  |  |  | No            |                  2 | On Loan: No      |
| Invesco Government & Agency Portfolio | Invesco Government & Agency Portfolio, Institutional Class | CUSIP: 825252885<br>LEI: 5493007T1J7WZ5QI1A47 | Long             | STIV             | RF                | US        |  13585536 | NS      | $13585536.29  | 1.02%             |  |  |  | No            |                  1 | On Loan: No      |
| argenx SE                             | argenx SE, ADR                                             | CUSIP: 04016X101<br>LEI: 7245009C5FZE6G9ODQ71 | Long             | EC               | CORP              | NL        |     37892 | NS      | $14484217.00  | 1.09%             |  |  |  | No            |                  1 | On Loan: No      |
| Lantheus Holdings, Inc.               | Lantheus Holdings, Inc.                                    | CUSIP: 516544103<br>LEI: 5299005HUB5IOJGO7S39 | Long             | EC               | CORP              | US        |     29929 | NS      | $1720917.50   | 0.13%             |  |  |  | No            |                  1 | On Loan: No      |
| Genmab A/S                            | Genmab A/S, ADR                                            | CUSIP: 372303206<br>LEI: 529900MTJPDPE4MHJ122 | Long             | EC               | CORP              | DK        |    195994 | NS      | $7673165.10   | 0.58%             |  |  |  | No            |                  1 | On Loan: —       |
| Acadia Healthcare Co., Inc.           | Acadia Healthcare Co., Inc.                                | CUSIP: 00404A109<br>LEI: 5493005CW985Y9D0NC11 | Long             | EC               | CORP              | US        |    110906 | NS      | $9318322.12   | 0.70%             |  |  |  | No            |                  1 | On Loan: No      |
| Silk Road Medical, Inc.               | Silk Road Medical, Inc.                                    | CUSIP: 82710M100<br>LEI: 549300VL8KC0ZPDQHE14 | Long             | EC               | CORP              | US        |     92695 | NS      | $5038900.20   | 0.38%             |  |  |  | No            |                  1 | On Loan: No      |
| Merck & Co., Inc.                     | Merck & Co., Inc.                                          | CUSIP: 58933Y105<br>LEI: 4YV9Y5M8S0BRK1RP0397 | Long             | EC               | CORP              | US        |    622892 | NS      | $66904829.72  | 5.04%             |  |  |  | No            |                  1 | On Loan: No      |
| 10x Genomics, Inc.                    | 10x Genomics, Inc., Class A                                | CUSIP: 88025U109<br>LEI: 5493003Z6741WNLG7H43 | Long             | EC               | CORP              | US        |     36268 | NS      | $1698430.44   | 0.13%             |  |  |  | No            |                  1 | On Loan: No      |
| Intra-Cellular Therapies, Inc.        | Intra-Cellular Therapies, Inc.                             | CUSIP: 46116X101<br>LEI: 5299002U2KGF193IJA20 | Long             | EC               | CORP              | US        |     83473 | NS      | $4000026.16   | 0.30%             |  |  |  | No            |                  1 | On Loan: No      |
| Bio-Techne Corp.                      | Bio-Techne Corp.                                           | CUSIP: 09073M104<br>LEI: 54930073RLKQ51TILZ35 | Long             | EC               | CORP              | US        |     37537 | NS      | $2990197.42   | 0.23%             |  |  |  | No            |                  1 | On Loan: No      |
| Becton, Dickinson and Co.             | Becton, Dickinson and Co.                                  | CUSIP: 075887109<br>LEI: ICE2EP6D98PQUILVRZ91 | Long             | EC               | CORP              | US        |     38540 | NS      | $9720558.80   | 0.73%             |  |  |  | No            |                  1 | On Loan: No      |
| Molina Healthcare, Inc.               | Molina Healthcare, Inc.                                    | CUSIP: 60855R100<br>LEI: 549300NQQCEQ46YHZ591 | Long             | EC               | CORP              | US        |     56068 | NS      | $17483684.44  | 1.32%             |  |  |  | No            |                  1 | On Loan: No      |
| Cytokinetics, Inc.                    | Cytokinetics, Inc.                                         | CUSIP: 23282W605<br>LEI: 549300BE5DY1HW7IHA64 | Long             | EC               | CORP              | US        |     51827 | NS      | $2201610.96   | 0.17%             |  |  |  | No            |                  1 | On Loan: —       |
| Globus Medical, Inc.                  | Globus Medical, Inc., Class A                              | CUSIP: 379577208<br>LEI: 5299003M2P4CIK0RF205 | Long             | EC               | CORP              | US        |    114436 | NS      | $8639918.00   | 0.65%             |  |  |  | No            |                  1 | On Loan: —       |
| AtriCure, Inc.                        | AtriCure, Inc.                                             | CUSIP: 04963C209<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     95647 | NS      | $4139602.16   | 0.31%             |  |  |  | No            |                  1 | On Loan: No      |
| INVESCO PRIVATE GOVERNMENT FUND       | INVESCO PRIVATE GOVERNMENT FUND                            | CUSIP: N/A<br>LEI: N/A                        | Long             | STIV             | PF                | US        |   9466816 | NS      | $9466816.10   | 0.71%             |  |  |  | No            |                  2 | On Loan: No      |
| Encompass Health Corp.                | Encompass Health Corp.                                     | CUSIP: 29261A100<br>LEI: 549300FVRPM9DRQZRG64 | Long             | EC               | CORP              | US        |     79801 | NS      | $4983572.45   | 0.38%             |  |  |  | No            |                  1 | On Loan: No      |
| AstraZeneca PLC                       | AstraZeneca PLC, ADR                                       | CUSIP: 046353108<br>LEI: PY6ZZQWO2IZFZC3IOL08 | Long             | EC               | CORP              | GB        |    557703 | NS      | $36457045.11  | 2.74%             |  |  |  | No            |                  1 | On Loan: No      |
| Lonza Group AG                        | Lonza Group AG                                             | CUSIP: N/A<br>LEI: 549300EFW4H2TCZ71055       | Long             | EC               | CORP              | CH        |      4584 | NS      | $2616890.79   | 0.20%             |  |  |  | No            |                  2 | On Loan: No      |
| McKesson Corp.                        | McKesson Corp.                                             | CUSIP: 58155Q103<br>LEI: 549300WZWOM80UCFSF54 | Long             | EC               | CORP              | US        |     78471 | NS      | $29715398.28  | 2.24%             |  |  |  | No            |                  1 | On Loan: No      |
| Sarepta Therapeutics, Inc.            | Sarepta Therapeutics, Inc.                                 | CUSIP: 803607100<br>LEI: 549300IKDPIED8J8IG21 | Long             | EC               | CORP              | US        |     47185 | NS      | $5896709.45   | 0.44%             |  |  |  | No            |                  1 | On Loan: No      |
| Alnylam Pharmaceuticals, Inc.         | Alnylam Pharmaceuticals, Inc.                              | CUSIP: 02043Q107<br>LEI: 529900S3ZI14OWRJII50 | Long             | EC               | CORP              | US        |     59846 | NS      | $13549134.40  | 1.02%             |  |  |  | No            |                  1 | On Loan: No      |
| Ascendis Pharma A/S                   | Ascendis Pharma A/S, ADR                                   | CUSIP: 04351P101<br>LEI: 549300B66JN3W3J8GH73 | Long             | EC               | CORP              | DK        |     23555 | NS      | $2922704.40   | 0.22%             |  |  |  | No            |                  1 | On Loan: No      |
| Axsome Therapeutics, Inc.             | Axsome Therapeutics, Inc.                                  | CUSIP: 05464T104<br>LEI: 549300EXGR0XLRJEIB95 | Long             | EC               | CORP              | US        |     29000 | NS      | $2175000.00   | 0.16%             |  |  |  | No            |                  1 | On Loan: —       |
| Dexcom, Inc.                          | Dexcom, Inc.                                               | CUSIP: 252131107<br>LEI: 549300YSK3QDSFR5EU59 | Long             | EC               | CORP              | US        |    190788 | NS      | $20431486.92  | 1.54%             |  |  |  | No            |                  1 | On Loan: No      |
| Surgery Partners, Inc.                | Surgery Partners, Inc.                                     | CUSIP: 86881A100<br>LEI: 549300LC82HG33S19I03 | Long             | EC               | CORP              | US        |    193939 | NS      | $6438774.80   | 0.48%             |  |  |  | No            |                  1 | On Loan: No      |
| INVESCO PRIVATE PRIME FUND            | INVESCO PRIVATE PRIME FUND                                 | CUSIP: N/A<br>LEI: N/A                        | Long             | STIV             | PF                | US        |  24338474 | NS      | $24345775.01  | 1.83%             |  |  |  | No            |                  2 | On Loan: No      |
| Vertex Pharmaceuticals Inc.           | Vertex Pharmaceuticals Inc.                                | CUSIP: 92532F100<br>LEI: 54930015RAQRRZ5ZGJ91 | Long             | EC               | CORP              | US        |    132504 | NS      | $42812042.40  | 3.22%             |  |  |  | No            |                  1 | On Loan: No      |
| BioCryst Pharmaceuticals, Inc.        | BioCryst Pharmaceuticals, Inc.                             | CUSIP: 09058V103<br>LEI: 549300Z0INP1Z5NP6J59 | Long             | EC               | CORP              | US        |    131925 | NS      | $1391808.75   | 0.10%             |  |  |  | No            |                  1 | On Loan: —       |
| AMN Healthcare Services, Inc.         | AMN Healthcare Services, Inc.                              | CUSIP: 001744101<br>LEI: 529900W3ARRTCNFH2I39 | Long             | EC               | CORP              | US        |     47918 | NS      | $4592461.12   | 0.35%             |  |  |  | No            |                  1 | On Loan: No      |
| Legend Biotech Corp.                  | Legend Biotech Corp., ADR                                  | CUSIP: 52490G102<br>LEI: 254900EIUFZTW136H859 | Long             | EC               | CORP              | KY        |     55054 | NS      | $2780227.00   | 0.21%             |  |  |  | No            |                  1 | On Loan: —       |
| AstraZeneca PLC                       | AstraZeneca PLC                                            | CUSIP: N/A<br>LEI: PY6ZZQWO2IZFZC3IOL08       | Long             | EC               | CORP              | GB        |     40217 | NS      | $5261923.49   | 0.40%             |  |  |  | No            |                  2 | On Loan: No      |
| Insulet Corp.                         | Insulet Corp.                                              | CUSIP: 45784P101<br>LEI: 549300TZTYD2PYN92D43 | Long             | EC               | CORP              | US        |     51713 | NS      | $14858179.16  | 1.12%             |  |  |  | No            |                  1 | On Loan: No      |
| Karuna Therapeutics, Inc.             | Karuna Therapeutics, Inc.                                  | CUSIP: 48576A100<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     14296 | NS      | $2850479.44   | 0.21%             |  |  |  | No            |                  1 | On Loan: —       |
| Cooper Cos., Inc. (The)               | Cooper Cos., Inc. (The)                                    | CUSIP: 216648402<br>LEI: QJKMVPIGLH7530PCUE20 | Long             | EC               | CORP              | US        |     14506 | NS      | $5061578.58   | 0.38%             |  |  |  | No            |                  1 | On Loan: No      |
| ShockWave Medical, Inc.               | ShockWave Medical, Inc.                                    | CUSIP: 82489T104<br>LEI: 549300LDXO56IC5Y1538 | Long             | EC               | CORP              | US        |     49050 | NS      | $9217966.50   | 0.69%             |  |  |  | No            |                  1 | On Loan: No      |
| IDEXX Laboratories, Inc.              | IDEXX Laboratories, Inc.                                   | CUSIP: 45168D104<br>LEI: OGMTXK0LUU1HKV2P0J84 | Long             | EC               | CORP              | US        |     23438 | NS      | $11261959.00  | 0.85%             |  |  |  | No            |                  1 | On Loan: No      |
| Maravai LifeSciences Holdings, Inc.   | Maravai LifeSciences Holdings, Inc., Class A               | CUSIP: 56600D107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    147526 | NS      | $2162731.16   | 0.16%             |  |  |  | No            |                  1 | On Loan: No      |
| AdaptHealth Corp.                     | AdaptHealth Corp.                                          | CUSIP: 00653Q102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    108746 | NS      | $2330426.78   | 0.18%             |  |  |  | No            |                  1 | On Loan: No      |
| IQVIA Holdings Inc.                   | IQVIA Holdings Inc.                                        | CUSIP: 46266C105<br>LEI: 549300W3R20NM4KQPH86 | Long             | EC               | CORP              | US        |     48273 | NS      | $11074308.93  | 0.83%             |  |  |  | No            |                  1 | On Loan: No      |
| Agilent Technologies, Inc.            | Agilent Technologies, Inc.                                 | CUSIP: 00846U101<br>LEI: QUIX8Y7A2WP0XRMW7G29 | Long             | EC               | CORP              | US        |    184139 | NS      | $28003859.12  | 2.11%             |  |  |  | No            |                  1 | On Loan: No      |
| Humana Inc.                           | Humana Inc.                                                | CUSIP: 444859102<br>LEI: 529900YLDW34GJAO4J06 | Long             | EC               | CORP              | US        |     90008 | NS      | $46057093.60  | 3.47%             |  |  |  | No            |                  1 | On Loan: No      |
| Amgen Inc.                            | Amgen Inc.                                                 | CUSIP: 031162100<br>LEI: 62QBXGPJ34PQ72Z12S66 | Long             | EC               | CORP              | US        |     89600 | NS      | $22615040.00  | 1.70%             |  |  |  | No            |                  1 | On Loan: No      |
| Invesco Liquid Assets Portfolio       | Invesco Liquid Assets Portfolio                            | CUSIP: 825252729<br>LEI: 549300DC1W0JSX3QRC47 | Long             | STIV             | RF                | US        |  10352287 | NS      | $10355392.19  | 0.78%             |  |  |  | No            |                  1 | On Loan: No      |
| Halozyme Therapeutics, Inc.           | Halozyme Therapeutics, Inc.                                | CUSIP: 40637H109<br>LEI: 529900242I3SV9AGM753 | Long             | EC               | CORP              | US        |    188563 | NS      | $9761906.51   | 0.73%             |  |  |  | No            |                  1 | On Loan: —       |
| Inspire Medical Systems, Inc.         | Inspire Medical Systems, Inc.                              | CUSIP: 457730109<br>LEI: 549300XQQCQ7HCJKTW25 | Long             | EC               | CORP              | US        |     46682 | NS      | $11813346.92  | 0.89%             |  |  |  | No            |                  1 | On Loan: No      |
| Privia Health Group, Inc.             | Privia Health Group, Inc.                                  | CUSIP: 74276R102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    113291 | NS      | $3063388.64   | 0.23%             |  |  |  | No            |                  1 | On Loan: —       |
| Inari Medical, Inc.                   | Inari Medical, Inc.                                        | CUSIP: 45332Y109<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     44092 | NS      | $2515448.60   | 0.19%             |  |  |  | No            |                  1 | On Loan: —       |
| iRhythm Technologies, Inc.            | iRhythm Technologies, Inc.                                 | CUSIP: 450056106<br>LEI: 549300FJI72RJGDQS384 | Long             | EC               | CORP              | US        |     41132 | NS      | $4043275.60   | 0.30%             |  |  |  | No            |                  1 | On Loan: No      |
| Evolent Health, Inc.                  | Evolent Health, Inc., Class A                              | CUSIP: 30050B101<br>LEI: 549300CZOCFHQ2BBTR11 | Long             | EC               | CORP              | US        |    147949 | NS      | $4766916.78   | 0.36%             |  |  |  | No            |                  1 | On Loan: No      |
| HCA Healthcare, Inc.                  | HCA Healthcare, Inc.                                       | CUSIP: 40412C101<br>LEI: 529900PH4ZGUH2MNEU89 | Long             | EC               | CORP              | US        |     51071 | NS      | $13026679.97  | 0.98%             |  |  |  | No            |                  1 | On Loan: No      |
| Elevance Health, Inc.                 | Elevance Health, Inc.                                      | CUSIP: 036752103<br>LEI: 8MYN82XMYQH89CTMTH67 | Long             | EC               | CORP              | US        |     33495 | NS      | $16747165.05  | 1.26%             |  |  |  | No            |                  1 | On Loan: No      |
| Intuitive Surgical, Inc.              | Intuitive Surgical, Inc.                                   | CUSIP: 46120E602<br>LEI: 54930052SRG011710797 | Long             | EC               | CORP              | US        |    113636 | NS      | $27919228.84  | 2.10%             |  |  |  | No            |                  1 | On Loan: No      |
| AbbVie Inc.                           | AbbVie Inc.                                                | CUSIP: 00287Y109<br>LEI: FR5LCKFTG8054YNNRU85 | Long             | EC               | CORP              | US        |    374821 | NS      | $55379802.75  | 4.17%             |  |  |  | No            |                  1 | On Loan: No      |
| Regeneron Pharmaceuticals, Inc.       | Regeneron Pharmaceuticals, Inc.                            | CUSIP: 75886F107<br>LEI: 549300RCBFWIRX3HYQ56 | Long             | EC               | CORP              | US        |     41988 | NS      | $31846638.36  | 2.40%             |  |  |  | No            |                  1 | On Loan: No      |
| Gilead Sciences, Inc.                 | Gilead Sciences, Inc.                                      | CUSIP: 375558103<br>LEI: 549300WTZWR07K8MNV44 | Long             | EC               | CORP              | US        |    114354 | NS      | $9598874.76   | 0.72%             |  |  |  | No            |                  1 | On Loan: No      |
| UnitedHealth Group Inc.               | UnitedHealth Group Inc.                                    | CUSIP: 91324P102<br>LEI: 549300GHBMY8T5GXDE41 | Long             | EC               | CORP              | US        |    238401 | NS      | $119007395.19 | 8.96%             |  |  |  | No            |                  1 | On Loan: No      |
| Thermo Fisher Scientific Inc.         | Thermo Fisher Scientific Inc.                              | CUSIP: 883556102<br>LEI: HCHV7422L5HDJZCRFL38 | Long             | EC               | CORP              | US        |     91896 | NS      | $52411045.68  | 3.94%             |  |  |  | No            |                  1 | On Loan: No      |
| Guardant Health, Inc.                 | Guardant Health, Inc.                                      | CUSIP: 40131M109<br>LEI: 254900M8C3E5VC8BR186 | Long             | EC               | CORP              | US        |     54363 | NS      | $1708629.09   | 0.13%             |  |  |  | No            |                  1 | On Loan: —       |
| Incyte Corp.                          | Incyte Corp.                                               | CUSIP: 45337C102<br>LEI: 549300Z4WN6JVZ3T4680 | Long             | EC               | CORP              | US        |    170369 | NS      | $14505216.66  | 1.09%             |  |  |  | No            |                  1 | On Loan: No      |
| Roche Holding AG                      | Roche Holding AG                                           | CUSIP: N/A<br>LEI: 549300U41AUUVOAAOB37       | Long             | EC               | CORP              | CH        |     16483 | NS      | $5151487.37   | 0.39%             |  |  |  | No            |                  2 | On Loan: No      |
| Harmony Biosciences Holdings, Inc.    | Harmony Biosciences Holdings, Inc.                         | CUSIP: 413197104<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     70914 | NS      | $3415927.38   | 0.26%             |  |  |  | No            |                  1 | On Loan: No      |
| AmerisourceBergen Corp.               | AmerisourceBergen Corp.                                    | CUSIP: 03073E105<br>LEI: AI8GXW8LG5WK7E9UD086 | Long             | EC               | CORP              | US        |    177579 | NS      | $30003747.84  | 2.26%             |  |  |  | No            |                  1 | On Loan: No      |
| IVERIC bio, Inc.                      | IVERIC bio, Inc.                                           | CUSIP: 46583P102<br>LEI: 549300GZXI59U71XPM70 | Long             | EC               | CORP              | US        |    147129 | NS      | $3398679.90   | 0.26%             |  |  |  | No            |                  1 | On Loan: No      |
| Moderna, Inc.                         | Moderna, Inc.                                              | CUSIP: 60770K107<br>LEI: 549300EI6OKH5K5Q2G38 | Long             | EC               | CORP              | US        |     32630 | NS      | $5744837.80   | 0.43%             |  |  |  | No            |                  1 | On Loan: No      |
| Zoetis Inc.                           | Zoetis Inc.                                                | CUSIP: 98978V103<br>LEI: 549300HD9Q1LOC9KLJ48 | Long             | EC               | CORP              | US        |     68314 | NS      | $11305283.86  | 0.85%             |  |  |  | No            |                  1 | On Loan: No      |

### Signature

**Date Signed:** 2023-03-02

**Name of Applicant:** AIM Investment Funds (Invesco Investment Funds)

**Signature:** Sheri Morris

**Name of Signer:** Sheri Morris

**Title:** President